Fontan Patient Survival After Pediatric Heart Transplantation Has Improved in the Current Era Kathleen E. Simpson, MD, Elizabeth Pruitt, MSPH, James K. Kirklin, MD, David C. Naftel, PhD, Rakesh K. Singh, MD, MS, R. Erik Edens, MD, PhD, Aliessa P. Barnes, MD, Charles E. Canter, MD The Annals of Thoracic Surgery Volume 103, Issue 4, Pages 1315-1320 (April 2017) DOI: 10.1016/j.athoracsur.2016.08.110 Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Hazard analysis shows survival in Fontan patients after transplant (A) in the early era (1993 to 2006) and (B) late era (2007 to 2014). The range bars show the SD, and the dashed lines show the 70% confidence interval. (PHTS = Pediatric Heart Transplant Study.) The Annals of Thoracic Surgery 2017 103, 1315-1320DOI: (10.1016/j.athoracsur.2016.08.110) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Hazard analysis of survival after transplant for non-Fontan patients in the (A) in the early era (1993 to 2006) and (B) late era (2007 to 2014). The range bars show the SD, and the dashed lines show the 70% confidence interval. (PHTS = Pediatric Heart Transplant Study.) The Annals of Thoracic Surgery 2017 103, 1315-1320DOI: (10.1016/j.athoracsur.2016.08.110) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 Kaplan-Meier analysis of survival comparison between groups and across eras. Fontan patient postheart transplant survival significantly improved from the early to late era. (CHD = congenital heart disease; PHTS = Pediatric Heart Transplant Study.) The Annals of Thoracic Surgery 2017 103, 1315-1320DOI: (10.1016/j.athoracsur.2016.08.110) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions